Retapamulin(SB-275833) is a topical antibiotic, which binds to both E. coli and S. aureus ribosomes with similar potencies with Kd of 3 nM. IC50 Value: 3 nM(Kd, E.coli) Target: Antibacterial Retapamulin is a topical antibiotic developed by GlaxoSmithKline. Retapamulin(SB-275833) is the first drug in the new class of pleuromutilin antibiotics to be approved for human use.Retapamulin(SB-275833) is marketed as an ointment under the brand names Altabax and Altargo. Retapamulin(SB-275833) is useful for Antibiotics.

• [1]. Kircik LH. Efficacy and tolerability of retapamulin 1% ointment for the treatment of infected atopic dermatitis: a pilot study. J Drugs Dermatol. 2012 Jul 1;11(7):858-60.

  [2]. Candel FJ, Morales G, Picazo JJ. In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates. Rev Esp Quimioter. 2011 Sep;24(3):127-30.

  [3]. Pérez-Trallero E, Tamayo E, Montes M, García-Arenzana JM, Iriarte V. In vitro activities of retapamulin and 16 other antimicrobial agents against recently obtained Streptococcus pyogenes isolates. Antimicrob Agents Chemother. 2011 May;55(5):2406-8.

  [4]. Weinberg JM, Tyring SK. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol. 2010 Oct;9(10):1198-204.

  [5]. Retapamulin: focus on its use in the treatment of uncomplicated superficial skin infections and impetigo By Jacobs, Michael R.From Expert Review of Dermatology (2010), 5(5), 505-517.